Sign In
Buy CDNA
$47.07
+0.380 (+0.81%)
At Close: Aug 10, 2026
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 07'th Aug 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of in
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:45pm, Friday, 31'st Jul 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 3
Why CareDx Stock Jumped Today
05:24pm, Friday, 31'st Jul 2026
CareDx is helping to improve outcomes for transplant patients. The health monitor's non-invasive tests are in high demand.
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
09:13pm, Thursday, 30'th Jul 2026
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
06:26pm, Thursday, 30'th Jul 2026
CareDx (CDNA) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.1 per share a year ago.
CareDx Q2 Earnings Call Highlights
06:06pm, Thursday, 30'th Jul 2026
CareDx NASDAQ: CDNA reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integr
CareDx Announces Second Quarter 2026 Financial Results
04:01pm, Thursday, 30'th Jul 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial result
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
11:01am, Thursday, 23'rd Jul 2026
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA
03:15am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. raised its holdings in shares of CareDx, Inc. (NASDAQ: CDNA) by 2.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The instituti
CareDx's Growth Prospects With Naveris Keep Me Bullish
08:15am, Monday, 20'th Jul 2026
CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA's AlloHeme gives them longer-term optionali
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
06:20am, Friday, 17'th Jul 2026
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
08:35am, Thursday, 16'th Jul 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
08:30am, Thursday, 16'th Jul 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization o
CareDx Completes Naveris Acquisition and Expands Oncology Reach
12:26pm, Tuesday, 07'th Jul 2026
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
08:01am, Tuesday, 07'th Jul 2026
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products div
